Skip to content

Non-invasive testing to aid in the diagnosis of allergies using fingermark depositions

Non-invasive testing to aid in the diagnosis of allergies using fingermark depositions - Allergy diagnosis using fingermarks

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON45058
Enrollment
60
Registered
2014-03-21
Start date
2015-02-12
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergy hypersensitive

Interventions

None listed

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - rhiniconjunctivitis +/- asthma - allergic symptoms, provocation after contact with trees, grass, mites, dogs and/or cats. - positieve skin pricktest for specific allergen in consistency with symptoms -18 years and older. - mentally competent - no comorbidity which interferes with the skin prick test;control subject: - no rhinoconjunctivitis, asthma of eczema - 18 years or older - mentally competent - no comorbidity - negative skinpricktest

Exclusion criteria

Exclusion criteria: - younger than 18 years - not mentally competent - comorbidity, which interferes with the skinprick test -negative skin prick test

Design outcomes

Primary

MeasureTime frame
Positive reaction after the skin prick test, whereby a drop of a solution containing the allergen is placed on the skin, next to this a serie of needle pricks allows the solution to enter the skin, resulting in a red, raised itchy area (called a wheal). Positive staining after incubation of a specific allergen in the fingermark. Negative reaction after injection of a specific allergen after the skin prick test. Negative staining after incuabation of a specific allergen in the fingermark ( no staining). Determination of specific allergies in as well the intracutaneous skin prick test as the fingermark. Saliva will be used as control --> Increased or no increased level of total IgE

Secondary

MeasureTime frame
-

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)